GSA Capital Partners LLP Boosts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

GSA Capital Partners LLP boosted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 2,962.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 966,202 shares of the biopharmaceutical company's stock after acquiring an additional 934,649 shares during the quarter. GSA Capital Partners LLP owned 0.42% of Sangamo Therapeutics worth $634,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SGMO. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Sangamo Therapeutics by 12.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company's stock worth $125,000 after buying an additional 13,518 shares during the period. LPL Financial LLC lifted its stake in shares of Sangamo Therapeutics by 113.5% during the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 16,498 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Sangamo Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company's stock worth $406,000 after purchasing an additional 17,049 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 21,793 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Sangamo Therapeutics by 40.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 95,501 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 27,353 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Analysts Set New Price Targets

SGMO has been the topic of several recent analyst reports. Wall Street Zen lowered Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Barclays cut their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Sangamo Therapeutics presently has an average rating of "Hold" and an average price target of $4.50.

Sangamo Therapeutics Trading Up 4.6%

Shares of SGMO stock opened at $0.56 on Monday. The company has a market capitalization of $130.95 million, a P/E ratio of -1.44 and a beta of 1.18. The business's 50 day moving average is $0.51 and its two-hundred day moving average is $0.74. Sangamo Therapeutics, Inc. has a 12-month low of $0.41 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analysts' expectations of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. On average, research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.